<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312256</url>
  </required_header>
  <id_info>
    <org_study_id>19-011705</org_study_id>
    <nct_id>NCT04312256</nct_id>
  </id_info>
  <brief_title>Thumb vs Great Toe Recovery</brief_title>
  <official_title>Comparison of Flexor Hallicus Brevis and Adductor Pollicis as Sites for Neuromuscular Monitoring With Electromyography (Thumb vs Great Toe) After Sugammadex Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researches are comparing the accuracy of measuring muscle relaxation in the thumb versus the
      great toe.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consistency of values between flexor hallucis brevis and adductor pollicis muscles</measure>
    <time_frame>Up to 1 hour postoperatively</time_frame>
    <description>Obtain TetraGraph values in both flexor hallucis brevis and adductor pollicis muscles simultaneous (same measuring units).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of residual neuromuscular blockade</measure>
    <time_frame>Up to 1 hour postoperatively</time_frame>
    <description>Number of patients with train of four ratio &lt; 0.9 after administration of reversal agent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Residual Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group 1: Dominant Hand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and great toe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Non-Dominant Hand</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the non-dominant hand and great toe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TetraGraph</intervention_name>
    <description>FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.</description>
    <arm_group_label>Group 1: Dominant Hand</arm_group_label>
    <arm_group_label>Group 2: Non-Dominant Hand</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18 years old

          -  Patients willing to participate and provide an informed consent

          -  Patients undergoing an elective surgical procedure that requires use of
             non-depolarizing NMBA agents administered intraoperatively.

          -  Patients with planned administration of sugammadex as a neuromuscular blocking
             reversal agent.

        Exclusion Criteria:

          -  Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with
             nerve damage, Dupuytren contracture, or any similar wrist injury.

          -  Patients with systemic neuromuscular diseases such as myasthenia gravis

          -  Patients with significant organ dysfunction that can significantly affect
             pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal
             impairment or end-stage liver disease.

          -  Patients having surgery that would involve prepping the arm or leg into the sterile
             field
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.Ross Renew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>J. Ross Renew, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neuromuscular Blockade</keyword>
  <keyword>Tetragraph</keyword>
  <keyword>AMG</keyword>
  <keyword>EMG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

